Mytos has secured new deals with a trio of clinical-stage biotechs, broadening use of its platform to advance therapies targeting bone defects, deafness, and blindness.
Automated cell manufacturer Mytos said it has secured new partnerships with a trio of clinical-stage biotechs, expanding the use of its platform to study potential therapies for bone defects, deafness and blindness.
The London-headquartered cell therapy maker will be working with Belgium-headquartered Novadip, UK-based Rinri Therapeutics and Finland’s StemSight, the company told Endpoints News. No financial details were disclosed.
Novadip is the most clinically advanced of the three companies. The biotech will use Mytos’ platform to make its clinical-stage autologous cell therapies for bone defects. Novadip’s lead project is an autologous cell therapy asset, dubbed NVD-003, which is being investigated in two Phase 3 studies for rare pediatric bone defects, according to its website.
As for Rinri, it will use Mytos’ platform to manufacture its main asset, called Rincell-1, which is due to enter its first human trial for sensorineural hearing loss. The company got the go-ahead from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) to start the study in July.
StemSight, meanwhile, will use the same platform to advance its lead candidate for limbal stem cell deficiency, which is a rare form of blindness where limbal stem cells are damaged, causing the eye’s cornea to start to break down.
Mytos’ three new partnerships add to one it announced in January with Aspen Neuroscience. That biotech is using the company’s platform to make its Parkinson’s disease cell therapy codenamed ANPD001.
The manufacturer’s automated platform converts stem cells into other cell types for companies to use in their therapy development.
Typically, this process is done manually, which takes time and is more costly, requiring the need for a large team to operate equipment, CEO Ali Afshar told Endpoints in an interview. Mytos’ platform removes this operational hurdle and allows companies to scale up their manufacturing faster, he added.
The company closed a $19 million Series A in November 2023. Afshar said it is looking to launch a Series B “very soon,” but did not provide details.
